XML 48 R38.htm IDEA: XBRL DOCUMENT
v3.22.1

SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended
--- | --- | ---
May 31, 2021 | Sep. 30, 2019 | Mar. 31, 2022 | Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | $ 7,109 | $ 2,408
Affiliated Entity | Mundipharma Medical Company | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 0 | 0
Affiliated Entity | Mundipharma Medical Company | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 2,526 | 2,408
Affiliated Entity | Mundipharma Medical Company | License of Intellectual Property |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  | $ 17,900 |  |
Affiliated Entity | Mundipharma Medical Company | Research and Development Services | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 0 | 0
Affiliated Entity | Mundipharma Medical Company | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 2,274 | 2,331
Affiliated Entity | Mundipharma Medical Company | Clinical Supply Services | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 0 | 0
Affiliated Entity | Mundipharma Medical Company | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 252 | $ 77
Affiliated Entity | Janssen Pharmaceuticals, Inc. | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 816 |
Affiliated Entity | Janssen Pharmaceuticals, Inc. | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 3,767 |
Affiliated Entity | Janssen Pharmaceuticals, Inc. | License of Intellectual Property |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue | $ 27,000 |  |  |
Affiliated Entity | Janssen Pharmaceuticals, Inc. | License of Intellectual Property | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 816 |
Affiliated Entity | Janssen Pharmaceuticals, Inc. | License of Intellectual Property | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 0 |
Affiliated Entity | Janssen Pharmaceuticals, Inc. | Research and Development Services | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 0 |
Affiliated Entity | Janssen Pharmaceuticals, Inc. | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 2,356 |
Affiliated Entity | Janssen Pharmaceuticals, Inc. | Clinical Supply Services | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | 0 |
Affiliated Entity | Janssen Pharmaceuticals, Inc. | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  |  | $ 1,411 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |